Opendata, web and dolomites

DMD2CURE

Correction of duplications in the DMD gene by a CRISPR/Cas9 approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DMD2CURE project word cloud

Explore the words cloud of the DMD2CURE project. It provides you a very rough idea of what is the project "DMD2CURE" about.

alterations    induce    technologies    premises    sequences    genome    mutations    therapies    identical    dystrophin    progressive    grna    removing    almost    sequence    deletion    skeletal    leiden    fibrosis    milestones    model    pathologies    promises    exonic    deletions    dystrophy    duplications    therapy    inversion    coding    nucleases    tools    termination    muscle    synthetic    molecular    diseases    respiratory    pave    muscular    feasible    live    strategy    motor       delayed       followed    protein    frequent    10    500    limited    shift    sites    births    recessive    frame    restoring    male    reported    therapeutic    mutation    exon    occurs    introduce    database    expression    editing    treatment    gene    applicable    disorder    intronic    skipping    uses    disease    arena    regions    tandem    translation    represented    necrosis    chose    contiguous    crispr    generally    exist    weakening    date    hold    employ    linked    deleted    repair    cardiac    revolutionizing    duchenne    despite    duplication    cas9    wasting    incidence    dmd    premature   

Project "DMD2CURE" data sheet

The following table provides information about the project.

Coordinator
ASSOCIATION GENETHON 

Organization address
address: RUE DE L INTERNATIONALE 1 BIS
city: EVRY
postcode: 91002
website: www.genethon.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.genethon.fr/en/
 Total cost 185˙076 €
 EC max contribution 185˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSOCIATION GENETHON FR (EVRY) coordinator 185˙076.00

Map

 Project objective

Duchenne muscular dystrophy is an X-linked recessive muscle-wasting disease, characterized by progressive weakening of skeletal, respiratory, and cardiac muscle followed by necrosis and fibrosis. DMD affects ~1:3,500 live male births and is associated with delayed motor milestones. DMD occurs as a result of mutations within the DMD gene that lead to premature termination of translation. The most frequent type of mutations are exonic deletions and duplications that induce a frame-shift in the protein-coding sequence. To date no effective treatment exist for this disorder. Duplications account for ~5–10% of all reported mutations in DMD in the Leiden database, although the incidence may be higher. Despite the limited number in DMD, duplications are widespread in almost all diseases and are generally neglected by therapeutic approaches. New molecular tools, now represented by genome-editing technologies that use synthetic nucleases in order to introduce targeted alterations at specific sites in the genome, hold great promises for revolutionizing the gene therapy arena. According to these premises, we propose a novel strategy based on the CRISPR/Cas9 system to repair tandem duplications by removing the mutation: compared to the exon deletions approach which uses two gRNA targeting two unique regions defining the sequence to be deleted, our approach will employ only one gRNA against a unique intronic sequence within the tandem duplication. This strategy will exploit the characteristic of tandem duplication (two identical contiguous sequences) and will result in the deletion or inversion of the mutation restoring the dystrophin expression. As a model we chose the exon 2 duplication which is the most frequent one in the DMD gene, but the same approach would be applicable to all tandem duplications. This study will pave the way for the development of therapies against duplications also in pathologies in which the exon skipping approach is not feasible.

 Publications

year authors and title journal last update
List of publications.
2017 Annalisa Lattanzi, Stephanie Duguez, Arianna Moiani, Araksya Izmiryan, Elena Barbon, Samia Martin, Kamel Mamchaoui, Vincent Mouly, Francesco Bernardi, Fulvio Mavilio, Matteo Bovolenta
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
published pages: 11-19, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2017.02.004
Molecular Therapy - Nucleic Acids 7 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DMD2CURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DMD2CURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

TeamUp (2020)

Understanding and improving team decision making in uncertain environments

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More